Isomorphic Labs raises 2.1 billion US dollars in Series B funding

The AI biotech company Isomorphic Labs has closed a Series B financing round of 2.1 billion US dollars. The round is led by Thrive Capital. Also participating are existing investors Alphabet and GV as well as new investors such as MGX, Temasek, CapitalG and the UK Sovereign AI Fund.

Isomorphic Labs intends to use the capital to massively expand its AI-supported drug discovery platform, drive global expansion and accelerate the development of its own drug programs.

Drug development is the next billion-dollar market for AI

While generative AI has so far mainly been associated with chatbots and productivity tools, drug discovery is increasingly becoming one of the most strategically important AI markets worldwide. Isomorphic Labs was founded in 2021 and is led by Demis Hassabis. He is best known as the co-founder of DeepMind and one of the most influential figures in modern AI research.

The company's vision goes far beyond traditional software: the development of new drugs is to be fundamentally accelerated with the help of proprietary AI models.

AI drug engine to radically accelerate research

The company's proprietary platform "IsoDDE" is at the heart of the strategy. This is an AI drug design engine that analyzes biological systems and can identify potential drug candidates. According to the company, this should enable new drugs to be developed significantly faster, more precisely and more efficiently than with traditional research processes.

Now that we have shown that our approach works in principle, our focus is on scaling the technology to its full potential.

Demis Hassabis, CEO Isomorphic Labs raises 2.1 billion US dollars in Series B

President Max Jaderberg also emphasizes the speed of the platform:"Our drug design engine works - and it gives us a repeatable way to develop new drugs for a variety of diseases."

Partnerships with pharmaceutical giants

Isomorphic Labs is already working with some of the largest pharmaceutical companies in the world. These include Novartis, Eli Lilly and Company and Johnson & Johnson. These partnerships are seen as an important validation factor for the company's approach and demonstrate the extent to which the pharmaceutical industry is now relying on AI technologies.

The scale of the financing round also underlines how strategically relevant AI has become for the future of the global healthcare industry. Investors see AI-supported drug development not only as an efficiency gain, but potentially as a complete paradigm shift in research and clinical development. Joshua Kushner, founder of Thrive Capital, speaks of a"new era of drug development".

Europe's answer to the AI biotech offensive from the USA

With its headquarters in London and locations in Cambridge (Massachusetts) and Lausanne, Isomorphic Labs is increasingly positioning itself as a European counterpart to the major American AI biotech players. This is positive news, considering that there have been reports of plant closures in Germany in recent days, particularly from BioNTech and Curavec.

The company combines cutting-edge AI research with biology, chemistry and clinical development, an area that is likely to be one of the most capital-intensive technology markets worldwide in the coming years. The current financing is already one of the largest AI biotech rounds in Europe.